Home › Funds › Arbiter Partners Capital Management LLC › RNA
Arbiter Partners Capital Management LLC position in RNA
ATRIUM THERAPEUTICS INC · Health Care
Arbiter Partners Capital Management LLC reported holding 311,719 shares of RNA (ATRIUM THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$2.6M, representing 1.14% of its reported portfolio and ranking #17 among its reported holdings. Arbiter Partners Capital Management LLC has disclosed RNA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Arbiter Partners Capital Management LLC's RNA position evolved
Arbiter Partners Capital Management LLC first disclosed a stake in RNA in Q1 2026 at 230,000 shares (US$3.1M). The position peaked in Q2 2026 at 261,288 shares, worth US$3.5M. Across 3 filings, Arbiter Partners Capital Management LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 311,719 shares valued at US$2.6M — an increase of 50,431 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 230.00K | $3.08M | New |
| Q2 2026 | 261.29K | $3.51M | Add |
| Q3 2026 | 311.72K | $2.58M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RNA and 13F data
RNA (ATRIUM THERAPEUTICS INC) is a Health Care company. 98 other funds we track also report a position in RNA — the largest reported positions include Sessa Capital IM, L.P. (US$20.2M), TIG Advisors, LLC (US$7.6M), Slotnik Capital, LLC (US$3.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RNA
- Sessa Capital IM, L.P. 1.50M sh · $20.18M · Q2 2026
- TIG Advisors, LLC 561.53K sh · $7.55M · Q2 2026
- Slotnik Capital, LLC 237.64K sh · $3.20M · Q2 2026
- NEXPOINT ASSET MANAGEMENT, L.P. 150.03K sh · $2.02M · Q2 2026
- Bracebridge Capital, LLC 139.24K sh · $1.87M · Q2 2026
- Marble Bar Asset Management LLP 103.85K sh · $1.40M · Q2 2026
- Kalehua Capital Management LLC 112.65K sh · $932.76K · Q3 2026
- Athos Capital Ltd 107.97K sh · $894.00K · Q3 2026
- Trium Capital LLP 58.38K sh · $483.40K · Q3 2026
- ALETHEA CAPITAL MANAGEMENT, LLC 43.76K sh · $362.32K · Q3 2026
- Twin Securities, Inc. 26.52K sh · $356.65K · Q2 2026
More on Arbiter Partners Capital Management LLC
FAQ
How long has Arbiter Partners Capital Management LLC held RNA?
Arbiter Partners Capital Management LLC has disclosed RNA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Arbiter Partners Capital Management LLC's current position in RNA?
As of Q3 2026, Arbiter Partners Capital Management LLC holds 311.72K shares of RNA (ATRIUM THERAPEUTICS INC), valued at $2.58M, representing 1.14% of its reported portfolio and ranking #17.
Has Arbiter Partners Capital Management LLC been buying or selling RNA?
In the latest 13F filing (Q3 2026), Arbiter Partners Capital Management LLC increased its position in RNA. The position peaked in Q2 2026 at 261.29K shares.
Which other funds hold RNA?
Other major institutional holders of RNA include Sessa Capital IM, L.P., TIG Advisors, LLC, Slotnik Capital, LLC, among 98 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.